Cargando…
Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8(+) T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy
Oncolytic virotherapy has garnered attention as an antigen-agnostic therapeutic cancer vaccine that induces cancer-specific T cell responses without additional antigen loading. As anticancer immune responses are compromised by a lack of antigenicity and chronic immunosuppressive microenvironments, a...
Autores principales: | Jeon, Yun-Hui, Lee, Namhee, Yoo, Jiyoon, Won, Solchan, Shin, Suk-kyung, Kim, Kyu-Hwan, Park, Jun-Gyu, Kim, Min-Gang, Kim, Hang-Rae, Oh, Keunhee, Lee, Dong-Sup |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027961/ https://www.ncbi.nlm.nih.gov/pubmed/35453555 http://dx.doi.org/10.3390/biomedicines10040805 |
Ejemplares similares
-
Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies
por: Lee, Namhee, et al.
Publicado: (2023) -
Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment
por: Park, Jee Soo, et al.
Publicado: (2022) -
Mass‐produced gram‐negative bacterial outer membrane vesicles activate cancer antigen‐specific stem‐like CD8(+) T cells which enables an effective combination immunotherapy with anti‐PD‐1
por: Won, Solchan, et al.
Publicado: (2023) -
Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009) -
Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes
por: Cho, Euna, et al.
Publicado: (2020)